Log in

Evgen Pharma Share Forecast, Price & News

GBX 11.88
0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: GBX 11.88
50-Day Range
MA: GBX 13.18
52-Week Range
Now: GBX 11.88
Volume204,202 shs
Average Volume1.53 million shs
Market Capitalization£16.30 million
P/E RatioN/A
Dividend YieldN/A
Evgen Pharma plc, a clinical stage drug development company, focuses on the treatment of cancer and neurological diseases. Its core technology is Sulforadex, which include synthetic and stabilized analogues of the naturally occurring compound sulforaphane. The company's lead product is SFX-01, a synthetic version of sulforaphane stabilised that is in Phase II clinical trials for the treatment of breast cancer and subarachnoid haemorrhage, as well as in preclinical stage for multiple sclerosis and clinical stage to treat prostate cancer. Evgen Pharma plc was founded in 2007 and is headquartered in Wilmslow, the United Kingdom.
Read More
Evgen Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.60 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic



Sales & Book Value

Annual SalesN/A
Cash FlowGBX 3.04 per share
Book ValueGBX 3.20 per share



Market Cap£16.30 million
Next Earnings DateN/A
OptionableNot Optionable
GBX 11.88
0.00 (0.00 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive EVG News and Ratings via Email

Sign-up to receive the latest news and ratings for EVG and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Evgen Pharma (LON:EVG) Frequently Asked Questions

How has Evgen Pharma's stock price been impacted by Coronavirus (COVID-19)?

Evgen Pharma's stock was trading at GBX 4.45 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EVG shares have increased by 166.9% and is now trading at GBX 11.88.
View which stocks have been most impacted by COVID-19

How were Evgen Pharma's earnings last quarter?

Evgen Pharma PLC (LON:EVG) announced its quarterly earnings data on Monday, June, 15th. The company reported ($2.10) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($2.10).
View Evgen Pharma's earnings history

Who are some of Evgen Pharma's key competitors?

What other stocks do shareholders of Evgen Pharma own?

Who are Evgen Pharma's key executives?

Evgen Pharma's management team includes the following people:
  • Dr. Stephen J. Franklin, CEO & Exec. Director
  • Mr. Richard Anthony Moulson, CFO & Exec. Director (Age 57)
  • Ms. Liz Jenkins, Regulatory Consultant
  • Dr. Thomas Morris, Consultant & Medical Advisor of Oncology
  • Prof. Albena Dinkova-Kostova, Independent Scientific Advisor

What is Evgen Pharma's stock symbol?

Evgen Pharma trades on the London Stock Exchange (LON) under the ticker symbol "EVG."

How do I buy shares of Evgen Pharma?

Shares of EVG and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Evgen Pharma's stock price today?

One share of EVG stock can currently be purchased for approximately GBX 11.88.

How big of a company is Evgen Pharma?

Evgen Pharma has a market capitalization of £16.30 million. Evgen Pharma employs 11 workers across the globe.

What is Evgen Pharma's official website?

The official website for Evgen Pharma is evgen.com.

How can I contact Evgen Pharma?

Evgen Pharma's mailing address is The Colony 146 Brownlow Hill, Altrincham Road, WILMSLOW, SK9 4LY, United Kingdom. The company can be reached via phone at +44-151-7053532.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.